- Home
- PPBT vs GXAI Comparison
PPBT vs GXAI Comparison
Compare PPBT & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- GXAI
- Stock Information
- Founded
- PPBT 2010
- GXAI 2021
- Country
- PPBT Israel
- GXAI United States
- Employees
- PPBT N/A
- GXAI N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- GXAI
- Sector
- PPBT Health Care
- GXAI
- Exchange
- PPBT Nasdaq
- GXAI Nasdaq
- Market Cap
- PPBT 6.5M
- GXAI 7.3M
- IPO Year
- PPBT N/A
- GXAI 2023
- Fundamental
- Price
- PPBT $2.27
- GXAI $1.32
- Analyst Decision
- PPBT Strong Buy
- GXAI
- Analyst Count
- PPBT 1
- GXAI 0
- Target Price
- PPBT $33.00
- GXAI N/A
- AVG Volume (30 Days)
- PPBT 286.5K
- GXAI 97.7K
- Earning Date
- PPBT 05-23-2025
- GXAI 05-27-2025
- Dividend Yield
- PPBT N/A
- GXAI N/A
- EPS Growth
- PPBT N/A
- GXAI N/A
- EPS
- PPBT N/A
- GXAI N/A
- Revenue
- PPBT N/A
- GXAI $27,740.00
- Revenue This Year
- PPBT N/A
- GXAI N/A
- Revenue Next Year
- PPBT N/A
- GXAI N/A
- P/E Ratio
- PPBT N/A
- GXAI N/A
- Revenue Growth
- PPBT N/A
- GXAI 1473.05
- 52 Week Low
- PPBT $2.00
- GXAI $1.00
- 52 Week High
- PPBT $20.60
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- PPBT 40.43
- GXAI 60.39
- Support Level
- PPBT $2.18
- GXAI $1.07
- Resistance Level
- PPBT $2.41
- GXAI $1.44
- Average True Range (ATR)
- PPBT 0.20
- GXAI 0.08
- MACD
- PPBT -0.01
- GXAI 0.03
- Stochastic Oscillator
- PPBT 27.96
- GXAI 67.57
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.